BCL2 and acute myeloid leukemia: The combination of the BCL-2 inhibitor venetoclax and the hypomethylating drug azacitidine constitutes the standard of care for patients with newly diagnosed AML who are at least 75 years old or who have preexisting comorbidities precluding them from intensive chemotherapy [9].